Fig. 1
From: Zoledronic acid ameliorates the effects of secondary osteoporosis in rheumatoid arthritis patients
Sixty-six eligible participants were randomized into three treatment groups and followed for 1 year for clinical outcomes on DAS28, VAS, ESR, CRP, BMD, and FRAX.